CTT PHARMACEUTICAL HOLDINGS, INC.
CTTH evidence brief
What we can confirm
- BioSniper Score:
- 7.6 / 10
- Market Cap:
- $2.8M
What it means
What to watch
Prepared research question
What matters most for CTTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTTH
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) is a development-stage company focused on a patented oral delivery system for pharmaceuticals and nutraceuticals, with no reported revenue and limited assets as of its most recent filings.
Key risk: Funding uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 8 clinical trials for CTT PHARMACEUTICAL HOLDINGS, INC..
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) is a development-stage company focused on a patented oral delivery system for pharmaceuticals and nutraceuticals, with no reported revenue and limited assets as of its most recent filings.
- CTT Pharma specializes in a patented oral delivery system for medications including cannabis [sec · filed 2015-07-21].
- As of the most recent filing (2026-07-24), the company generated revenue from a partnership with Aurora but has limited assets [sec · filed 2026-07-24].
- Shareholders' equity was $0.0M as of 2026-06-30 [sec].
- The company has not generated any revenues historically and has limited assets [sec · filed 2014-11-28].
- Future operating results depend on raising adequate working capital, success in developing and marketing the oral delivery system, and other factors [sec · filed 2026-07-24].
What works
- The company has a patented oral delivery technology that it continues to develop and commercialize [sec · filed 2015-10-08].
- As of 2026-07-24, the company reported generating revenue from a partnership with Aurora, indicating some commercial traction [sec · filed 2026-07-24].
- Management and directors have significant experience in the medical field [sec · filed 2026-07-24].
What to weigh
- The company has limited assets and historically no revenues, with shareholders' equity at $0.0M as of 2026-06-30 [sec] [sec · filed 2014-11-28].
- There is no assurance that the company will be able to secure adequate funding to meet its obligations and pursue its strategic direction [sec · filed 2015-10-08].
- Further development and commercialization entail substantial risk and require significant operational expenditures [sec · filed 2015-10-08].
- The company's future operating results depend on many uncertain factors, including raising working capital and market demand [sec · filed 2026-07-24].
From the filings
Quoted directly from source documents.
The company specializes in an oral delivery system for medications including cannabis.
“system for medications including cannabis.”
SEC filings · November 28, 2014
As of the most recent filing, the company generated revenue from a partnership with Aurora.
“As of the date of this report, we generated revenue from our partnership with Aurora.”
SEC filings · July 24, 2026
The company has limited assets and no historical revenues.
“As of the date of this report, we have not generated any revenues and have limited assets.”
SEC filings · November 28, 2014
There is no assurance of securing adequate funding.
“There can be no assurances, however, that the Company will be able to secure adequate funding to meet its current obligations and successfully pursue its strategic direction.”
SEC filings · October 8, 2015
Risks & what to watch (4)›
Key risks
- Funding uncertainty — No assurance of securing adequate working capital to meet obligations and pursue strategy [sec · filed 2015-10-08].
- Zero shareholders' equity — Shareholders' equity reported as $0.0M as of 2026-06-30, indicating minimal financial cushion [sec].
- Dependence on unproven technology — Success depends on developing and marketing the oral delivery system, which entails substantial risk [sec · filed 2026-07-24].
- Limited revenue history — Historically no revenues; only recent partnership revenue reported, with limited assets [sec · filed 2014-11-28] [sec · filed 2026-07-24].
What to watch
- Ability to raise additional working capital and secure funding for continued operations [sec · filed 2026-07-24].
- Progress in developing and commercializing the oral delivery system, including any new partnerships or revenue streams [sec · filed 2026-07-24].
- Changes in shareholders' equity and cash position in future financial filings [sec].
- Any updates on the partnership with Aurora and its contribution to revenue [sec · filed 2026-07-24].
Sources: Catalysts · SEC filings · Generated September 29, 2026 · How we verify sources →
Run CTT PHARMACEUTICAL HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CTT PHARMACEUTICAL HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.59
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
8 buys · 0 sells (180d)
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for CTT PHARMACEUTICAL HOLDINGS, INC.?
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) is a development-stage company focused on a patented oral delivery system for pharmaceuticals and nutraceuticals, with no reported revenue and limited assets as of its most recent filings.
Who is the CEO of CTT PHARMACEUTICAL HOLDINGS, INC.?
Mr. Ryan Khouri is the chief executive officer of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH).
Where is CTT PHARMACEUTICAL HOLDINGS, INC. headquartered?
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) is headquartered in Tampa, FL, United States.
What therapeutic areas does CTT PHARMACEUTICAL HOLDINGS, INC. focus on?
CTT PHARMACEUTICAL HOLDINGS, INC. develops therapies across Oncology, Infectious Disease, Respiratory, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.